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Rare genetic variants can cause epilepsy, and genetic testing has been widely adopted for severe, paediatric-onset epilepsies. The
phenotypic consequences of common genetic risk burden for epilepsies and their potential future clinical applications have not yet
been determined. Using polygenic risk scores (PRS) from a European-ancestry genome-wide association study in generalized and
focal epilepsy, we quantiﬁed common genetic burden in patients with generalized epilepsy (GE-PRS) or focal epilepsy (FE-PRS)
from two independent non-Finnish European cohorts (Epi25 Consortium, n = 5705; Cleveland Clinic Epilepsy Center, n = 620;
both compared to 20 435 controls). One Finnish-ancestry population isolate (Finnish-ancestry Epi25, n = 449; compared to 1559
controls), two European-ancestry biobanks (UK Biobank, n = 383656; Vanderbilt biorepository, n = 49 494), and one Japanese-
ancestry biobank (BioBank Japan, n = 168 680) were used for additional replications. Across 8386 patients with epilepsy and
622212 population controls, we found and replicated signiﬁcantly higher GE-PRS in patients with generalized epilepsy of
European-ancestry compared to patients with focal epilepsy (Epi25: P = 1.641015; Cleveland: P = 2.85104; Finnish-ancestry
Epi25: P = 1.80104) or population controls (Epi25: P = 2.351070; Cleveland: P = 1.43107; Finnish-ancestry Epi25: P =
3.11104; UK Biobank and Vanderbilt biorepository meta-analysis: P = 7.99104). FE-PRS were signiﬁcantly higher in
patients with focal epilepsy compared to controls in the non-Finnish, non-biobank cohorts (Epi25: P = 5.741019; Cleveland:
P = 1.69106). European ancestry-derived PRS did not predict generalized epilepsy or focal epilepsy in Japanese-ancestry
individuals. Finally, we observed a signiﬁcant 4.6-fold and a 4.5-fold enrichment of patients with generalized epilepsy compared
to controls in the top 0.5% highest GE-PRS of the two non-Finnish European cohorts (Epi25: P = 2.601015; Cleveland: P =
1.39102). We conclude that common variant risk associated with epilepsy is signiﬁcantly enriched in multiple cohorts of
patients with epilepsy compared to controls—in particular for generalized epilepsy. As sample sizes and PRS accuracy continue
to increase with further common variant discovery, PRS could complement established clinical biomarkers and augment genetic
testing for patient classiﬁcation, comorbidity research, and potentially targeted treatment.
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Introduction
Epilepsy is a common chronic neurological disorder,
affecting approximately 1% of individuals (Ngugi et al.,
2010). Lifetime prevalence is 8–10% for a seizure and 3–
4% for epilepsy (Hesdorffer et al., 2011). The median
incidence of epilepsy is 50 per 100 000 person-years
(Ngugi et al., 2011). Individuals at high risk for recurrent
seizures (epilepsy) beneﬁt from early antiseizure drug
treatment, compared to no treatment or delayed treat-
ment (Kim et al., 2006). Predicting whether an individual
will develop epilepsy after the ﬁrst epileptic seizure is difﬁcult
(MacDonald et al., 2000; Bell et al., 2016), with recurrence
risk varying from 27% to 71% (Hopkins et al., 1988; Berg
and Shinnar, 1991; Kwan and Sander, 2004).
Epileptic seizures either have a generalized (involving
both cerebral hemispheres) or a focal (originating from
one cerebral hemisphere) onset (Scheffer et al., 2017).
Generalized epilepsies account on average for 54%, focal
epilepsies for 40%, and unclassiﬁable epilepsies for 7% of
incident epilepsies in population-based studies of all ages
(Banerjee et al., 2009). Distinguishing between the two
types of epilepsy can be difﬁcult: focal epilepsy can present
with bilateral tonic-clonic seizures (secondary-generaliza-
tion), patients with generalized epilepsy can have focal fea-
tures on EEG (Japaridze et al., 2016), and some individuals
have a mix of focal and generalized epilepsy (Scheffer et al.,
2017). Since commonly used antiseizure drugs for focal
epilepsy can be ineffective or exacerbate generalized epilep-
sies, differentiating between focal and generalized epilepsy
is important (Japaridze et al., 2016). Hence, there is a clin-
ical need for biomarkers that can help to distinguish
individuals at high versus low risk to develop either focal
or generalized epilepsy.
Genetic factors can explain a substantial portion of cases
of epilepsy, particularly severe epilepsy (EpiPM Consortium
et al., 2015). For rare and early onset childhood epilepsies,
4100 epilepsy-related genes have been discovered in recent
years (Heyne et al., 2019). The identiﬁed genetic variants
are rare and of large effect, ranging from large deletions
that confer on average 7-fold risk for epilepsy (Pe´rez-
Palma et al., 2017) to single, causative de novo variants
in 433 genes (Heyne et al., 2018). These variants are diag-
nostically relevant and can inﬂuence patient management.
For example, treatment with sodium channel blockers can
exacerbate seizures in patients with Dravet syndrome or
other early-onset epileptic syndromes caused by SCN1A
mutations, whereas these drugs are beneﬁcial in patients
with gain-of-function variants in SCN2A (Guerrini et al.,
1998; Lo¨scher, 2009; Wolff et al., 2017). While rare vari-
ation of large effect has a clear impact in clinical practice
for rare epilepsy syndromes (McTague et al., 2016), pa-
tients affected by common types of epilepsy rarely carry
such variants and routine genetic testing is therefore not
established for the common epilepsies.
Genome-wide association studies (GWAS) for common
forms of epilepsy have identiﬁed common genetic risk vari-
ants for generalized epilepsy, focal epilepsy, and febrile
seizures (Kasperavicˇiu¯te_ et al., 2013; Feenstra et al., 2014;
International League Against Epilepsy Consortium on
Complex Epilepsies, 2014, 2018). Common genetic risk
variants associated with a disease are usually of small
effect size (1.33 median odds ratio) (Hindorff et al.,
2009) and cannot individually quantify risk or to inform
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prognosis and treatment. However, polygenic risk scores
(PRSs) that combine the effect sizes of thousands of vari-
ants into a single score can stratify affected and healthy
individuals. For ﬁve common disorders, a recent study
showed a 3- to 5-fold increased risk for patients with a
high disease-speciﬁc PRS, similar to the range of risk con-
ferred by rare monogenic variants, such as LDLR missense
variants for coronary artery disease or rare BRCA variants
in breast cancer (Khera et al., 2018). Based on these results,
the authors proposed that PRS-based prediction may be
reliable enough to consider their utility in clinical practice.
Genome-wide PRS based on thousands of common vari-
ants associated with epilepsy may help distinguish healthy
individuals from those who develop epilepsy (Speed et al.,
2014). However, no studies have directly investigated
whether PRSs derived from well-phenotyped cohorts stratify
patients in clinical practice or population-based cohort stu-
dies. Here, we calculate PRSs for the two main subtypes of
epilepsy (generalized and focal) from the largest GWAS in
epilepsy to date (International League Against Epilepsy
Consortium on Complex Epilepsies, 2018) and (i) quantify
the burden of PRSs derived from GWAS studies of well-phe-
notyped cohorts in patients with generalized or focal epi-
lepsy; (ii) explore if PRS can differentiate patients with
generalized from those with focal epilepsy; and (iii) explore
if patients with generalized or focal epilepsy are enriched
particularly in the upper extreme of the PRS burden distri-
bution compared to controls. Our overall study design is
presented in Fig. 1. Across two independent research cohorts,
one clinically ascertained cohort, and three biobanks (reposi-
tories with clinical data and DNA samples available for re-
search); data from 630598 individuals were available for the
PRS analyses.
Patients and methods
Study cohorts
Patients of European ancestry with generalized epilepsy or
focal epilepsy were recruited through the Epi25 project
(http://epi-25.org/), an international multicentre epilepsy gen-
etics research consortium [exploration cohorts for generalized
(GE) and focal (FE) epilepsy: GE-Epi25-EUR and FE-Epi25-
EUR, respectively] and from a single clinical centre, the
Cleveland Clinic Epilepsy Center (replication cohorts for gen-
eralized and focal epilepsy: GE-Cleveland-EUR and FE-
Cleveland-EUR, respectively). A Finnish-ancestry population
isolate was recruited from the Epi25 project (GE-Epi25-FIN
and FE-Epi25-FIN, respectively). Ancestry-matched population
controls were recruited from several in-house projects, the
Partners HealthCare Biobank (Karlson et al., 2016), and the
FINRISK study (Borodulin et al., 2017). Three large-scale bio-
bank repositories [UKB: UK Biobank (Sudlow et al., 2015);
BioVU: Vanderbilt University biorepository (Roden et al.,
2008); and BBJ: BioBank Japan (Nagai et al., 2017)] were
used for additional explorations. All cohorts, totalling
630 598 individuals, are detailed in Table 1 and the
Supplementary material.
Polygenic risk scoring in the study
cohorts
Single-nucleotide polymorphism (SNP) weights for PRS were
derived from summary statistics of the ILAE Consortium on
Complex Epilepsies GWAS for generalized and focal epilepsy
(International League Against Epilepsy Consortium on
Complex Epilepsies, 2018). SNP weights for negative control
PRS were derived from the UKB GWAS for type 2 diabetes for
all cohorts excluding the UKB, and from the DIAGRAM-type
2 diabetes GWAS (Scott et al., 2017) for the UKB. PRS for
each individual were generated using the allelic scoring func-
tion, as implemented in PLINK v1.9 (Chang et al., 2015).
Individual PRSs were calculated as the sum of weighted
effect alleles divided by the number of SNPs in the analysis.
We generated the PRSs at the P-value threshold 0.5, found to
be the best predicting threshold in a random split (80% train-
ing, 20% validation) of our exploration cohort (Epi25-EUR,
Supplementary material 4.8, Supplementary Tables 4 and 5).
We excluded individuals if their data were included in the
GWAS studies used for PRS development. Details of the
method to detect overlapping individuals across cohorts and
the SNP quality control applied are given in the Supplementary
material.
Statistical analysis
We used logistic regression adjusted for sex and for the ﬁrst
four principal components of ancestry to determine the ability
of PRS to stratify cases from controls. The proportion of
phenotypic variance explained by PRS was calculated using
Nagelkerke’s pseudo-R2, by comparing the full model of the
logistic regression (PRS plus all covariates: sex and the ﬁrst
four principal components of ancestry) to the null model (cov-
ariates only). Following the example of Khera et al. (2018) we
assessed the enrichment of the two epilepsy phenotypes (gen-
eralized epilepsy or focal epilepsy) in progressively more ex-
treme tails of the PRS distribution (top 20%, 5%, 0.5%)
against the remainder of the distribution in a logistic regression
model predicting disease status, adjusted for sex and the ﬁrst
four principal components of ancestry. The threshold for stat-
istical signiﬁcance after Bonferroni correction was set to  =
1.67  102 (three tests per cohort). Fixed-effect meta-ana-
lysis, with adjustment for the effective sample size, was per-
formed using METAL (Willer et al., 2010).
Data availability
The data that support the ﬁndings of this study are available
from the Epi25 Consortium, upon reasonable request. The
biobank data are available from the UKB, BioVU, and BBJ
upon successful project application.
Results
Higher PRS burden in patients with
epilepsy compared to controls
To determine if common variants associated with epilepsy
are enriched in independent cohorts of patients with
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Figure 1 Study design. (1) PRSs for the two main classes of epilepsy (generalized and focal) were derived from the largest GWAS in epilepsy
to date (International League Against Epilepsy Consortium on Complex Epilepsies, 2018). (2) PRS were calculated in patients with generalized or
focal epilepsy and in population controls and (3) tested in their ability to identify significant differences of common variant burden among groups.
(4) The UK and Vanderbilt biobanks were available to test the behaviour of the PRSs in individuals ascertained by ICD-10 codes for epilepsy, while
the Biobank Japan was available to test the performance in a non-European population. SNP = single nucleotide polymorphism.
Table 1 Study cohorts after quality control
Cohort name Ascertainment type Ethnicity Generalized epilepsy (GE) Focal epilepsy (FE) Controls
Epi25-EUR Research EUR 2256 3449 20 435
Cleveland-EUR Clinic EUR 85 535 20 435
Epi25-FIN Research FIN 112 337 1559
UKB Biobank EUR 246 213 383 197
BioVU Biobank EUR 293 536 48 665
BBJ Biobank JPN 219 105 168 356
Generalized and focal epilepsy were diagnosed in the Epi25-EUR, Cleveland-EUR, Epi25-FIN, and BBJ cohorts according to clinical criteria (clinical interview, neurological exam-
ination, EEG, imaging data). For the UK and BioVU biobanks, ICD-10 G40.3 codes were used to identify people with generalized epilepsy, and G40.0 to G40.2 codes to identify
people with focal epilepsy.
BBJ = BioBank Japan; BioVU = Vanderbilt University biorepository; Cleveland-EUR = European-ancestry Cleveland Clinic Epilepsy Center cohort; Epi25-EUR = European-ancestry
Epi25 cohort; Epi25-FIN = Finnish-ancestry Epi25 cohort; UKB = UK Biobank.
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generalized epilepsy or focal epilepsy compared to popula-
tion controls, we conducted a PRS analysis in two independ-
ent epilepsy cohorts of European ancestry. We found that in
the GE-Epi25-EUR cohort, genome-wide polygenic risk
scores for generalized epilepsy (GE-PRS) were signiﬁcantly
higher in patients with generalized epilepsy (n = 2256 cases)
than in population controls (n = 20435 controls; P =
2.35  1070; Fig. 2 and Supplementary Table 1). GE-PRS
explained 2.8% of the total phenotypic variance (composed
of genetic, environmental, and genetic-environmental inter-
action variances) among the case and control group of the
GE-Epi25-EUR cohort (Supplementary Table 1). This obser-
vation was replicated in the clinical GE-Cleveland-EUR
cohort (P = 1.43107; n = 85 cases; 2.6% phenotypic
variance explained). In the FE-Epi25-EUR cohort, the
genome-wide polygenic risk for focal epilepsy (FE-PRS)
was signiﬁcantly higher in patients with focal epilepsy (n =
3449 cases) than in population controls (P = 5.741019),
with 0.6% of the phenotypic variance explained. This ob-
servation was replicated in the clinical FE-Cleveland-EUR
cohort (n = 535; P = 1.69106; 0.5% phenotypic vari-
ance explained). As expected, PRSs for type 2 diabetes
(negative control) were not signiﬁcantly higher in patients
with generalized epilepsy or focal epilepsy than in popula-
tion controls (Fig. 2 and Supplementary Table 1).
To test the utility of PRSs across different populations,
we investigated the power of the PRS derived from the
European population in the isolated Finnish population.
The GE-PRS was signiﬁcantly higher in patients with gen-
eralized epilepsy (n = 112 cases) than in the population
controls (n = 1559 controls; P = 3.11104;
Supplementary Fig. 2 and Supplementary Table 2).
However, the PRSs explained less phenotypic variance
than generalized epilepsy cohorts of European ancestry
(2% phenotypic variance explained). The FE-PRS were
not signiﬁcantly different between Finnish patients with
focal epilepsy (n = 337 cases) and controls (P = 0.55).
Higher PRS burden in generalized
compared to focal epilepsy
To determine if common variants associated with general-
ized epilepsy are enriched in patients with generalized epi-
lepsy compared to patients with focal epilepsy, we regressed
the GE-PRS against the diagnosis of generalized epilepsy or
focal epilepsy. In the Epi25-EUR cohort, GE-PRSs were sig-
niﬁcantly higher in patients with generalized epilepsy than in
those with focal epilepsy (P = 1.641015), explaining
1.7% of the phenotypic variance (Supplementary Table 1).
This observation was replicated in the Cleveland-EUR
cohort (P = 2.85104, 3.9% phenotypic variance ex-
plained) and the Epi25-FIN cohort (P = 1.80104,
4.6% phenotypic variance explained, Supplementary Table
2). Overall, the PRS had the most predictive power in the
corresponding epilepsy phenotype group: GE-status was best
predicted by GE-PRS (P = 2.351070, 2.8% phenotypic
variance explained in Epi25-EUR) over FE-PRS (P =
1.711015, 0.6% phenotypic variance explained) and
FE-status was best predicted by FE-PRS (P = 5.741019,
0.6% phenotypic variance explained in Epi25-EUR) over
GE-PRS (P = 8.211018, 0.5% phenotypic variance ex-
plained, Supplementary Table 1).
Enrichment of patients with epilepsy
in the highest PRS burden percentile
To explore if the GE- and FE-PRS enrichment in patients
with epilepsy is due to a few patients with a very high
Figure 2 Genome-wide polygenic risk for generalized epilepsy or focal epilepsy in the exploration and replication cohorts.
Shown are the means of the standardized GE-, FE-, and type 2 diabetes-PRS with 95% confidence intervals for the European-ancestry population
controls (highlighted in blue; n = 20 435), the European-ancestry generalized epilepsy and focal epilepsy Epi25 exploration cohorts (highlighted in
green; GE-Epi25-EUR, n = 2256; FE-Epi25-EUR, n = 3449), and the European-ancestry generalized epilepsy and focal epilepsy Cleveland Clinic
replication cohorts (highlighted in red; GE-Cleveland-EUR, n = 85; FE-Cleveland-EUR, n = 535). The P-values for the differences between cases
and population controls are given as numbers. The threshold for statistical significance after Bonferroni correction was set to  = 1.67  102
(three tests per cohort).
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burden or due to many with a slightly elevated burden, we
characterized the epilepsy PRS distribution in the
European-ancestry cohorts. Patients with epilepsy and
population control subjects were ranked according to
their PRSs and tested for enrichment of patients with gen-
eralized epilepsy or focal epilepsy in the extreme tails of the
PRS distribution. Strikingly, in the combined GE-Epi25-
EUR and control cohorts, we observed a signiﬁcant 4.63-
fold enrichment of patients with generalized epilepsy in the
group with the highest GE-PRS (top 0.5%, P =
2.601015; involving 2.39% of the GE-Epi25-EUR
cohort; Table 2). This observation was replicated in the
clinical GE-Cleveland-EUR cohort (4.47-fold enrichment;
P = 1.39102; 3.53% of the GE-Cleveland-EUR
cohort). In the FE-Epi25-EUR cohort, we observed a sig-
niﬁcant 2-fold enrichment of patients with focal epilepsy in
the group with the highest FE-PRS (top 0.5%, P =
5.57104; 1.16% of the FE-Epi25-EUR cohort; Table
2). This observation was not replicated in the smaller clin-
ical FE-Cleveland-EUR cohort (P = 0.22). All patients with
top 0.5% highest PRS were found in the top decile of the
GE- and FE-PRS distributions of the Epi25-EUR cohort
(Supplementary Figs 3 and 4). Measures of the diagnostic
accuracy of the PRS are given in Supplementary Table 8.
Epilepsy PRSs have limited value in
biobank-derived cohorts based on
ICD-10 codes
To evaluate whether common epilepsy variants identiﬁed in
well-phenotyped patients are enriched in patient cohorts
ascertained from patient registries and biobanks, we ex-
tended our GE- and FE-PRS analyses to include three
biobank-derived cohorts. In the UKB and BioVU biobanks,
diagnosis was ascertained by ICD-10 codes for epilepsy and
by a standardized questionnaire for the attending phys-
icians in the BBJ biobank. Fixed-effect meta-analysis of
the two European biobanks (UKB and BioVU), adjusted
for the effective sample size (Willer et al., 2010), revealed
signiﬁcantly higher GE-PRS in individuals coded as having
generalized epilepsy than in population controls (P =
7.99104, 539 patients with generalized epilepsy against
431 862 population controls). However, the PRS explained
only very little of the phenotypic variance in each biobank
(UKB: 0.12% variance explained; BioVU: 0.19%). In the
BBJ, the GE-PRS were not signiﬁcantly different between
Japanese-ancestry patients with generalized epilepsy and
controls (P = 0.33, 219 patients with generalized epilepsy
against 168 356 controls). The FE-PRS were not signiﬁ-
cantly different between individuals coded as having focal
epilepsy and controls in any of the three studied biobanks
(UKB: P = 0.44; BioVU: P = 0.23; BBJ: P = 0.29). The
PRSs for type 2 diabetes (negative control) were not signiﬁ-
cantly different in patients with generalized epilepsy or
focal epilepsy than in population controls. The results in
the three biobanks are detailed in Supplementary Table 3.
Discussion
We identiﬁed a signiﬁcantly higher genetic burden for epi-
lepsy, as quantiﬁed by PRS, in independent cohorts of pa-
tients with epilepsy as compared to population controls.
While modest effect sizes preclude risk prediction based
on single common genetic variants, PRSs that combine
thousands of variants show predictive ability across a
Table 2 Enrichment of patients with epilepsy in the extreme tails of the PRS distribution
Reference
group
OR 95% CI P-value Cases/controls
upper PRS%
Cases/controls
lower PRS%
Sensitivity Specificity
GE–PRS / GE-Epi25
Top 20% of distribution Remaining 80% 2.04 1.86–2.25 4.61  1048 887/3652 1369/16 783 0.393 0.821
Top 5% of distribution Remaining 95% 2.39 2.06–2.76 4.39  1032 305/830 1951/19 605 0.135 0.959
Top 0.5% of distribution Remaining 99.5% 4.63 3.16–6.76 2.60  1015 54/60 2202/20 375 0.024 0.997
GE–PRS / GE-Cleveland
Top 20% of distribution Remaining 80% 2.09 1.33–3.28 1.31  103 35/4070 50/16 365 0.412 0.801
Top 5% of distribution Remaining 95% 2.02 1.00–3.72 3.44  102 11/1016 74/19 419 0.129 0.950
Top 0.5% of distribution Remaining 99.5% 4.47 1.07–12.6 1.39  102 3/100 82/20 335 0.035 0.995
FE–PRS / FE-Epi25
Top 20% of distribution Remaining 80% 1.35 1.24–1.48 2.32  1011 992/3785 2457/16 650 0.288 0.815
Top 5% of distribution Remaining 95% 1.44 1.25–1.66 7.74  107 292/903 3157/19 532 0.085 0.956
Top 0.5% of distribution Remaining 99.5% 2.00 1.34–2.95 5.57  104 40/80 3409/20 355 0.012 0.996
FE–PRS / FE-Cleveland
Top 20% of distribution Remaining 80% 1.49 1.22–1.82 1.04  104 148/4047 387/16 388 0.277 0.802
Top 5% of distribution Remaining 95% 1.55 1.09–2.14 1.17  102 40/1009 495/19 426 0.075 0.951
Top 0.5% of distribution Remaining 99.5% 1.83 0.62–4.32 0.22 5/100 530/20 335 0.009 0.995
Odds ratios (OR) and P-values were calculated by comparing those within the top 0.5, 5, and 20% of the PRS distribution, to the remainder of the PRS distribution in a logistic
regression model adjusted for sex and the first four principal components of ancestry. The threshold for statistical significance after Bonferroni correction was set to  = 1.67 x 102
(three tests per cohort). CI = confidence interval; EUR = European.
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range of complex traits and diseases, including neuro-
psychiatric disorders (Khera et al., 2018). In the setting of
a collaborative epilepsy genetics community, we demon-
strate that available datasets have reached an adequate
size to address the role of common genetic variants, each
with small effect sizes, in large populations of patients with
epilepsy. In line with previous studies showing signiﬁcant
differences between the genetic architectures of generalized
epilepsy and focal epilepsy (Speed et al., 2014;
International League Against Epilepsy Consortium on
Complex Epilepsies, 2018), we also show that patients
with generalized epilepsy have a signiﬁcantly higher
burden of common risk variants associated with general-
ized epilepsy than patients with focal epilepsy. The PRSs
perform similarly in a multicentre research cohort and in an
unselected—although much smaller—cohort ascertained
through routine clinical practice in one single hospital. In
contrast, signiﬁcant, but small differences of PRS burden in
large-scale biobanks provide evidence that ICD-10 epilepsy
codes are not the best substitutes for precise clinical classi-
ﬁcations by experts, despite our efforts to identify patients
with generalized or focal epilepsy using stringent ICD code
ﬁltering. In line with recent evidence, we observe that PRSs
derived from a European cohort have lower power when
applied to populations of different genetic architecture, as
observed in the cohorts of Finnish and Japanese ancestry
(Martin et al., 2017).
By evaluating the PRS distribution, we identify patients
with an effect size of polygenic variants at group level that
is comparable to those in other studies with rare variants of
large effect. Among the group of patients with high GE-
PRS (top 0.5% of cases and controls with the highest
scores), we observe an enrichment of patients with general-
ized epilepsy similar to that seen among carriers of estab-
lished genetic risk factors, such as copy number variations
and de novo variants: the largest copy number variation
burden study in epilepsy to date showed a 7.45-fold enrich-
ment of patients with generalized epilepsy (2.78% of all
patients with generalized epilepsy) among all hotspot
copy number variations carriers (cases/controls) (Pe´rez-
Palma et al., 2017). The largest de novo variant study in
neurodevelopmental disorders with epilepsy showed a 4.6-
fold excess of de novo variants in known genes associated
with developmental and epileptic encephalopathies in neu-
rodevelopmental disorders with epilepsy when compared to
those without epilepsy (Heyne et al., 2018). In this study,
we identify a 4.63-fold enrichment of patients with general-
ized epilepsy in the top 0.5% highest GE-PRS in the Epi25
exploration cohort (2.39% of patients with generalized epi-
lepsy) and a 4.47-fold enrichment of patients with general-
ized epilepsy in the top 0.5% highest GE-PRS in the clinical
replication cohort (3.53% of patients with generalized
epilepsy).
PRSs could have clinical implications for epilepsies be-
cause of their predictive power. Treatment with antiepilep-
tic drugs after the ﬁrst seizure has been debated, and the
decision to start pharmacological treatment is usually based
on relative risks, beneﬁts, and lifestyle factors. After the
ﬁrst seizure, 50% of individuals go on to have a second
seizure within 3–5 years, with most recurrences occurring
within the ﬁrst year (Kho et al., 2006; Wiebe et al., 2008).
Several factors can increase the risk of seizure recurrence,
including abnormal results on neurological examination,
brain imaging, or EEG, a family history of epilepsy, or a
personal history of remote symptomatic seizures (Wiebe et
al., 2008). Patients at high risk for recurrence have been
shown to beneﬁt from immediate antiepileptic drug treat-
ment after a ﬁrst seizure compared to no treatment or
delayed treatment (Kim et al., 2006). For an individual
with new-onset epilepsy, it is also critical to differentiate
between a focal versus generalized epilepsy to inform the
selection of the ﬁrst-line antiseizure drug (Perucca et al.,
1998; Goldenberg, 2010). Differential diagnosis is espe-
cially challenging for focal epilepsy patients with secondary
generalization or for those not found to have a relevant
lesion on magnetic resonance imaging scans. A PRS indi-
cating that a person is carrying an excessive amount of
common risk variants for epilepsy or for generalized
versus focal epilepsy could provide useful information for
clinicians in deciding when to begin, and what type of
treatment should be provided.
Future research should determine if and how well PRS
can improve existing prediction models when combined
with other factors, including established genetic risk factors
of individually larger effect. Although our study represents
the ﬁrst of its kind in epilepsy, it needs to be replicated in a
prospective setting. The predictive power of the PRS is
determined by the genetic homogeneity of the GWAS
from which the PRS is generated and that of the cohort
to which it is applied. For epilepsy, a strong Eurocentric
bias in the only available large scale GWAS is impeding
PRS prediction in non-European individuals. Possible
approaches to improve the predictive power in the non-
European population, such as including the target popula-
tion in the training data (Ma´rquez-Luna et al., 2017), have
been explored, but to realize the full potential of the PRS,
greater population diversity must be prioritized in future
GWAS studies (Martin et al., 2019). It is possible that
PRSs for focal epilepsies currently lack power because
this group is genetically and phenotypically more heteroge-
neous than the group of generalized epilepsy (Speed et al.,
2014; International League Against Epilepsy Consortium
on Complex Epilepsies, 2018). The clinical value of the
PRS will also be limited by the low prevalence rates of
epilepsy, leading to high negative predictive values, but
low positive predictive values. To facilitate the implemen-
tation of PRS into clinical practice, additional research with
larger, better-differentiated cohorts from different popula-
tions with well-characterized epilepsy phenotypes will be
needed.
In summary, common polygenic variant burden for epi-
lepsy can be measured and is differently distributed among
patients with epilepsy and controls as well as between the
two main epilepsy phenotypes (i.e. generalized and focal).
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PRS for epilepsies can provide physicians with an estimate
of an individual’s overall genetic risk for epilepsy that could
aid in early diagnosis and targeted treatment in the future.
In addition, a combination of rare and common variants
that may predispose an individual to develop epilepsy pro-
vides a chance for more informative prediction tools that
may lead to a paradigm shift from current practice in rare
disorder genetics (presence or absence of a Mendelian,
high-risk variant) to a liability threshold model that as-
sumes for each individual a continuous liability composed
of rare and common genetic risk variants.
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